摘要
目前糖尿病患病率越来越高,且相当大一部分合并心血管疾病,SGLT2抑制药及GLP-1受体激动药可从降糖、减重、降压、保护肾功等多个角度间接及直接地减少糖尿病患者的心血管不良事件和心血管病病死率。
At present, the prevalence of diabetes mellitus is getting higher and higher, and a considerable part of them have cardiovascular disease. SGLT2 inhibitors and GLP-1 receptor agonists can reduce cardiovascular adverse events and cardiovascular mortality in diabetic patients from the angles of reducing blood sugar, weight, blood pressure and kidney function.
作者
赵喆
杨丹丹
詹晓蓉
ZHAO Zhe;YANG Dandan;ZHAN Xiaorong(Third Department of Endocrinology, First Affiliated Hospital of Harbin Medical University, Harbin 150001, China)
出处
《临床与病理杂志》
2019年第6期1337-1341,共5页
Journal of Clinical and Pathological Research
